Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib

Table 1

Summary of previously reported cases of pulmonary toxicities of Osimertinib.

Article	Patient age/sex	Onset of symptoms	Symptoms	Diagnosis	Treatment	Outcome
Mamesaya et al. [4]	38 F	31 days	Dyspnea and low-grade fever	Drug-induced interstitial lung disease (ILD)	Withdrawal of medication	Resolution of ILD but progression of malignancy
Matsumoto et al. [5]	75 M	20 days	Generalized weakness and dyspnea	Drug-induced ILD (NSIP)	Methylprednisone 500 mg daily for 3 days, then prednisone 40 mg daily	Resolution of ILD following steroid taper
Yang et al. [3]	8 patients (no specifics)	Average of 5.1 months		ILD and one case of pneumonitis	Not described	3 patients resolved, 2 remained at end of study, and 3 patients deceased
Nie et al. [6]	32 M	4.5 months	Cough and dyspnea	Acute ILD	Dose reduction to 80 mg every other day and dexamethasone 10 mg daily	Improvement in infiltrates and symptoms
Lee et al. [7]	15 patients	24 weeks	None	Asymptomatic pulmonary opacities	None	No adverse events reported
Noonan et al. [8]	4 males (average age 57) and 3 females (average age 43)	8 weeks mean onset	None	Asymptomatic pulmonary opacities, mostly nodules and ground glass opacities	None	All patients had good outcomes
Tachi et al. [9]	77 F	14 days	Fever and hypoxia	Eosinophilic pneumonia due to Osimertinib	Withdrawal of medication	Gradual improvement in her symptoms